Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ACLX-002
i
Other names:
ACLX-002, ACLX 002, ARC-T/SPRX002, monovalent CD123-Specific Adapter/ARC-T
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Arcellx
Drug class:
CD123-targeted CAR-T immunotherapy
Related drugs:
‹
UCART123 (2)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
AVC-101 (0)
AVC-201 (0)
Autologous CAR-T cells (0)
CART123 (0)
CD123 CAR-T cell therapy (0)
CD123-CAR T cell therapy (0)
EQ (0)
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)
CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)
IM23 (0)
MB-102 (0)
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (0)
SENL401 (0)
anti-CD123 CAR-T (0)
UCART123 (2)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
AVC-101 (0)
AVC-201 (0)
Autologous CAR-T cells (0)
CART123 (0)
CD123 CAR-T cell therapy (0)
CD123-CAR T cell therapy (0)
EQ (0)
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)
CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)
IM23 (0)
MB-102 (0)
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (0)
SENL401 (0)
anti-CD123 CAR-T (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
CD123 expression
Acute Myelogenous Leukemia
CD123 expression
Acute Myelogenous Leukemia
ACLX-002
Sensitive: D – Preclinical
ACLX-002
Sensitive
:
D
ACLX-002
Sensitive: D – Preclinical
ACLX-002
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login